ADMA Biologics (NASDAQ:ADMA) Shares Gap Down - Should You Sell?

Key Points

• ADMA Biologics shares experienced a significant drop, opening at $15.85 compared to the previous close of $18.54.
• Recent analysts' evaluations show a mix of perspectives, with Raymond James upgrading their price target to $32.00, while Wall Street Zen downgraded the stock to a "sell" rating.
• The company's latest quarterly earnings report indicated a net margin of 45.01% and a revenue growth of 40.2% year-over-year, although it missed expectations for earnings per share.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $18.54, but opened at $15.85. ADMA Biologics shares last traded at $16.53, with a volume of 2,823,872 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th.

ADMA Biologics Price Performance

The firm has a market capitalization of $3.91 billion, a PE ratio of 19.07 and a beta of 0.38. The stock has a 50-day moving average price of $18.55 and a 200 day moving average price of $18.85. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%. The business's revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.13 earnings per share. Equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock worth $9,644,269 in the last three months. 3.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in shares of ADMA Biologics by 272.5% during the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after acquiring an additional 561,310 shares during the last quarter. New York State Teachers Retirement System raised its position in ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after purchasing an additional 108,800 shares in the last quarter. GAMMA Investing LLC raised its position in ADMA Biologics by 251.6% in the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock valued at $131,000 after purchasing an additional 4,715 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at about $201,000. Finally, Ameriprise Financial Inc. raised its position in shares of ADMA Biologics by 14.1% during the 4th quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock worth $12,274,000 after acquiring an additional 88,542 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.